Yahoo Finance • 24 days ago
HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria... Full story
Yahoo Finance • last month
HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conf... Full story
Yahoo Finance • last month
Company Logo The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIn... Full story
Yahoo Finance • 2 months ago
Investing.com - Celldex Therapeutics (NASDAQ:CLDX), a $1.6 billion market cap biotech company currently trading near $24, reported negative results from its barzolvolimab study in eosinophilic esophagitis (EoE), despite Cantor Fitzgerald... Full story
Yahoo Finance • 2 months ago
[Candlestick chart and data of financial market.] tadamichi Stock futures edged lower early Wednesday as investors awaited the release of the Federal Reserve’s July meeting minutes for fresh clues on the path of interest rates. Here are... Full story
Yahoo Finance • 2 months ago
[Scientist analyze biochemical samples in advanced scientific laboratory. Medical professional use microscope look microbiological developmental of viral. Biotechnology research in science lab.] Celldex Therapeutics (NASDAQ:CLDX [https://... Full story
Yahoo Finance • 2 months ago
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE... Full story
Yahoo Finance • 2 months ago
Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cell... Full story
Yahoo Finance • 2 months ago
CELLDEX THERAPEUTICS INC (NASDAQ:CLDX [https://www.chartmill.com/stock/quote/CLDX]) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, EPS NARROWLY BEATS EXPECTATIONS Celldex Therapeutics Inc released its second-quarter 2025 financial re... Full story
Yahoo Finance • 2 months ago
Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing... Full story
Yahoo Finance • 3 months ago
Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic urticaria, stands at a critical juncture as it navigates recent setbacks and prepares for crucial data readouts. With a marke... Full story
Yahoo Finance • 4 months ago
H.C. Wainwright reiterated its Buy rating and $50.00 price target on Celldex Therapeutics (NASDAQ:CLDX) following the company’s presentation of 76-week data from its Phase 2 trial of barzolvolimab in chronic spontaneous urticaria (CSU).... Full story
Yahoo Finance • 4 months ago
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE)... Full story
Yahoo Finance • 4 months ago
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE)... Full story
Yahoo Finance • 4 months ago
Jasper Therapeutics (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic spontaneous urticaria (CSU) and other mast-cell mediated diseases, has been garnering attention from investors and analysts alike.... Full story
Yahoo Finance • 4 months ago
Celldex Therapeutics , Inc. (NASDAQ:CLDX), currently valued at $1.41 billion, has been making waves in the biopharmaceutical industry with its lead candidate, barzolvolimab, a novel treatment for chronic spontaneous urticaria (CSU) and eos... Full story
Yahoo Finance • 4 months ago
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerabi... Full story
Yahoo Finance • 4 months ago
HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held i... Full story
Yahoo Finance • 4 months ago
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board... Full story
Yahoo Finance • 7 months ago
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tu... Full story